AJP - Endo Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 293: E1-E15, 2007. First published March 6, 2007; doi:10.1152/ajpendo.00421.2006
0193-1849/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/1/E1    most recent
00421.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cobelli, C.
Right arrow Articles by Rizza, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cobelli, C.
Right arrow Articles by Rizza, R.

Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests

Claudio Cobelli,1 Gianna Maria Toffolo,1 Chiara Dalla Man,1 Marco Campioni,1 Paolo Denti,1 Andrea Caumo,2 Peter Butler,3 and Robert Rizza4

1Department of Information Engineering, University of Padua, Padua, Italy; 2San Raffaele Scientific Institute, Milan, Italy; 3Larry Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, California; and 4Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota

Submitted 16 August 2006 ; accepted in final form 27 February 2007


    ABSTRACT
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 
Assessment of insulin secretion in humans under physiological conditions has been a challenge because of its complex interplay with insulin action and hepatic insulin extraction. The possibility of simultaneously assessing beta-cell function, insulin sensitivity, and hepatic insulin extraction under physiological conditions using a simple protocol is appealing, since it has the potential to provide novel insights regarding the regulation of fasting and postprandial glucose metabolism in diabetic and nondiabetic humans. In this Perspective, we review data indicating that an oral glucose tolerance test (OGTT) or a meal test is able to accomplish this goal when interpreted with the oral beta-cell minimal model. We begin by using the well-established intravenous minimal model to highlight how the oral minimal model was developed and how the oral assessment parallels that of an intravenous glucose tolerance test (IVGTT). We also point out the unique aspects of both approaches in relation to their ability to assess different aspects of the beta-cell secretory cascade. We review the ability of the oral model to concurrently measure insulin sensitivity and hepatic insulin extraction, thereby enabling it to quantitatively portray the complex relationship among beta-cell function, hepatic insulin extraction, and insulin action. In addition, data from 204 individuals (54 young and 159 elderly) who underwent both IVGTT and meal tolerance tests are used to illustrate how these different approaches provide complementary but differing insights regarding the regulation of beta-cell function in humans.

glucose tolerance; disposition index; oral glucose tolerance test; meal; intravenous glucose tolerance test


IT IS WELL ESTABLISHED that abnormalities in insulin secretion are an important determinant of diabetes mellitus and other states of glucose intolerance. However, assessment of beta-cell function in humans under physiological conditions has been a challenge because of its complex interplay with other key system variables (Fig. 1). Although beta-cell function commonly is inferred from plasma insulin concentrations, this approach introduces error due to the confounding effect of hepatic insulin extraction. On the other hand, concordant measurement of C-peptide and insulin concentrations enables simultaneous assessment of insulin secretion and hepatic insulin extraction. An additional difficulty is that measurement of insulin secretion alone provides limited insight because appropriateness of beta-cell function must be interpreted relative to the prevailing level of insulin action. Since the primary goal of most studies is to determine how alterations in beta-cell function as well as in insulin action and hepatic insulin extraction influence carbohydrate, fat, and protein metabolism, ideally these should be assessed under physiological conditions by using a single, simple physiological test, i.e., in the presence of glucose, amino acids, incretins, and neural signals.


Figure 1
View larger version (8K):
[in this window]
[in a new window]

 
Fig. 1. beta-Cell function is causally related to insulin sensitivity, since the glucose system is negatively feedback regulated.

 
What methods are available and what are their limitations? Table 1 provides a list of commonly used protocols with their advantages and limitations. Knowledge of basal plasma glucose and insulin concentrations provides important albeit limited information regarding beta-cell function and insulin action (34, 40, 63). In fact, basal concentrations only reflect a single point on the complex glucose-insulin dose-response curve and thus cannot provide insight regarding the ability of beta-cells to respond to rising and falling glucose concentrations such as typically occur after eating. Alternative approaches have been proposed to circumvent these limitations, based on both intravenous and oral protocols. Hyperinsulinemic euglycemic clamps (25) are able to measure insulin action at a given insulin concentration; however, they do not assess beta-cell function. In addition, since under conditions of daily living insulin concentrations virtually never remain at a constant elevated level for many hours, and since insulin is normally secreted into the portal vein rather than infused into a peripheral vein, hyperinsulinemic clamps are nonphysiological. Hyperglycemic clamps (25) and graded glucose infusions (11) can be used to assess beta-cell function but also are limited by their nonphysiological route and pattern of glucose delivery.


View this table:
[in this window]
[in a new window]

 
Table 1. Protocols: their attributes, and information content

 
Models of insulin secretion enable evaluation of beta-cell function following intravenous injection of a bolus of glucose, e.g., during an intravenous glucose tolerance test (IVGTT) (59) or after ingestion of glucose, e.g., an oral glucose tolerance test (OGTT), or a mixed meal (8). The oral perturbations are no doubt more physiological than the intravenous ones with the incretin effect in operation and with the meal being superior to OGTT because of the presence of nutrients, i.e., proteins and fat. Insulin action and hepatic insulin extraction also can be assessed by models during both IVGTT and OGTT or meal (5, 23, 57). It is worth noting that with respect to insulin action, models using the intravenous protocols are simpler to create than the oral ones, since the input into the circulation, i.e., the amount of glucose injected, is known. In contrast, measurement of insulin action during an oral protocol requires assessment of the systemic rate of appearance of the ingested glucose. It is for this reason that reliable models of the oral perturbation only recently have become available thanks to multiple tracer meal validation studies (21, 24).

Simultaneous assessment of beta-cell function, hepatic insulin extraction, and insulin sensitivity under physiological conditions with the use of a simple protocol is appealing, since it has the potential to provide novel insights regarding the regulation of fasting and postprandial glucose metabolism in diabetic and nondiabetic humans and to evaluate different approaches to restore appropriate beta-cell function by pharmacological means and to transplant or perhaps regenerative approaches in future. We review in this Perspective data indicating that an OGTT or a meal test can be used to simultaneously and quantitatively measure beta-cell function, hepatic insulin extraction, and insulin sensitivity. We begin with a schematic representation of the cellular events involved in the regulation of insulin secretion and then put into context which aspects of the secretory pathway are likely being examined during in vivo measurement of beta-cell function. Next, we employ the now widely used intravenous minimal model to highlight how the oral minimal model was developed and how the oral assessment parallels that of IVGTT. Finally, we point out the unique aspects of both approaches, particularly in relation to their ability to assess different parts of the beta-cell secretory cascade. Because of space limitations, we do not discuss the additional mechanistic information that can be gained by adding glucose tracers to the intravenous or oral protocols (22, 24, 58). We present recently published data from 204 individuals (54 young and 159 elderly) who underwent both IVGTT and meal tolerance tests to illustrate how these different approaches provide complimentary but differing insights regarding the regulation of beta-cell function in humans (2).


    WHY IT IS DIFFICULT
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 
Insulin secretion can be readily assessed during a glucose perturbation by measuring C-peptide concentrations and using deconvolution. This approach is simple and virtually model independent (28, 47). However, it is more difficult to measure beta-cell function, since this requires the rate of secretion to be interpreted in relation to the prevailing glucose concentration, i.e., to take into account changing glucose concentration on beta-cell response. To do so, the two time courses need to be related by some mechanistic causal relationship; in other words, an hypothesis, or as commonly phrased, a model, of beta-cell function is required. beta-cell function also needs to be interpreted in light of the prevailing insulin sensitivity. One possibility is to resort to a normalization of beta-cell function based on the disposition index paradigm, first introduced in 1981 (4), where beta-cell function is multiplied by insulin sensitivity. This concept, self-evident in Fig. 1, is more clearly illustrated in Fig. 2. Although regulation of carbohydrate tolerance is undoubtedly more complex, it is conceived that glucose tolerance of an individual is related to the product of beta-cell function and insulin sensitivity. In essence, different values of tolerance are represented by different hyperbolas, i.e., DI = beta-cell function x insulin sensitivity = constant, where DI is the disposition index. If an individual's beta-cells respond to a decrease in insulin sensitivity by adequately increasing insulin secretion (state II), the product of beta-cell function and insulin sensitivity (the disposition index) is unchanged, and normal glucose tolerance is retained. In contrast, if there is not an adequate compensatory increase in beta-cell function to the decreased insulin sensitivity (state 2), the individual develops glucose intolerance. Thanks to its intuitive and reasonable grounds, this measure of beta-cell functionality, which was first introduced for IVGTT, has become the method of choice also with other tests, such as clamp and OGTT. However, the glucose-insulin feedback system is more complex than the hyperbola paradigm, i.e., DI = beta-cell function x insulin sensitivity = constant. The relation between beta-cell function and insulin sensitivity is certainly describable by a nonlinear inverse relationship but is in all likelihood more general than an hyperbola, e.g., DI = beta-cell function x (insulin sensitivity){alpha} = constant. In addition, this seemingly simple concept hides several methodological issues that unless fully appreciated could lead to errors in interpretation, particularly when comparing different populations. Furthermore, since the effect of insulin on peripheral tissues is determined not only by the biological effect of insulin but also by the amount of insulin to which the tissue is exposed, changes in hepatic insulin extraction provide yet another dimension to the relationship between insulin secretion and action portrayed in Fig. 2.


Figure 2
View larger version (9K):
[in this window]
[in a new window]

 
Fig. 2. The importance of expressing beta-cell responsivity in relation to insulin sensitivity is illustrated by using the disposition index metric; i.e., the product of beta-cell responsivity and insulin sensitivity is assumed to be a constant. A normal subject reacts to impaired insulin sensitivity by increasing beta-cell responsivity (state II), whereas a subject with impaired tolerance does not (state 2). In state II, beta-cell responsivity is increased but the disposition index beta-cell metric is normal, whereas in state 2, beta-cell responsivity is normal but the disposition index is impaired.

 

    CELLULAR EVENTS IN beta-CELLS
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 
The insulin secretory pathway is complex and regulated by multiple factors including glucose, protein, fat, and incretins (Fig. 3). Exposure of beta-cells to an abrupt increment of glucose elicits biphasic insulin secretion (19), an observation that prompted interest in the intracellular events leading to insulin secretory vesicle discharge (31, 32), resulting in proposal of a two-pool model of insulin-filled vesicles, broadly defined as those available for immediate exocytosis (first phase) and a reserve pool from which granules needed to be mobilized to being available for secretion (second phase). Advances in live cell imaging of neuroendocrine cells have permitted insights on insulin vesicle trafficking and exocytosis (50). In beta-cells a subpopulation of secretory vesicles is closely related to, and presumably docked to, the cell membrane (44). Upon stimulation with glucose, a small fraction of docked vesicles discharge their contents, implying that first-phase secretion is derived from a subset of docked vesicles that have been termed the primed docked vesicles (1).


Figure 3
View larger version (36K):
[in this window]
[in a new window]

 
Fig. 3. Representative beta-cells discharging insulin into an islet capillary loop. Major steps preceding insulin secretion are synthesis (not shown), proinsulin processing to insulin and vesicle transport and docking to membrane, vesicle priming, and then insulin discharge from vesicle into capillary as either a fraction of insulin contents (kiss and run illustrated in cell A) or all insulin contents (exocytosis in cell B).

 
With continued glucose stimulation, new insulin secretory vesicles are directed to the cell membrane (43, 48). Indirect and, more recently, direct evidence suggest that vesicles targeted to membrane docking are those that were most recently synthesized (27). Since the duration of fusion appears to be very brief and not all insulin within the granule is released before the granule closes and reenters the cytoplasm, this process has been referred to as "kiss and run" (60). Thus the intensity of the stimulus, e.g., glucose concentration, for secretion may direct the quantity of hormone secreted by exocytosis not only by recruiting the number of primed vesicles to undergo exocytosis but also the extent to which these vesicles discharge their cargo. Both nonprimed and previously fused granules can be recycled back into the cytoplasm, where insulin within the granule is degraded.

The time course of the various steps involved in insulin secretory pathways is believed to differ substantially, with exocytosis occurring within seconds, docking and priming within 5–10 min, and synthesis and processing likely considerably longer. Therefore, different stimuli assess different aspects of this pathway. For example, the rapid increase in plasma insulin that occurs during the first few minutes after intravenous injection of glucose almost certainly is solely due to first-phase release of insulin from previously docked and primed granules. On the other hand, the rate of release of insulin during the first hour after ingestion of a mixed meal, i.e., when plasma glucose is rising (see below), is likely determined by multiple steps, e.g., processing, docking, and priming, involved in second-phase secretion, in addition to exocytosis.


    beta-CELL FUNCTION FROM BASAL MEASUREMENTS
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 
The easiest and thus most popular assessment of beta-cell function is the homeostatic responsivity index HOMA-B, derived from basal measurements of insulin and glucose (40). Recently, the use of C-peptide instead of insulin in HOMA-B has been encouraged to avoid the confounding effect of hepatic insulin extraction (63). Although HOMA-B is widely used because of its simplicity, it is worth pointing out that it reflects the release of insulin under nonstimulated conditions. The homeostatic model HOMA-S also provides an index of insulin sensitivity under nonstimulated conditions, thus permitting evaluation of beta-cell function in relation to the prevailing insulin action. It should be noted that an hyperbolic relationship between the two indexes is inherent in the calculation, since HOMA-B x HOMA-S is a function of basal glucose concentration such that the two measurements are, by definition, in a given subject hyperbolically inversely related provided basal glucose [and also basal insulin if the computer model HOMA-S (63) is used] remains constant (16). Recently, another basal insulin sensitivity index, QUICKI, has been derived (34). QUICKI and HOMA-S are highly correlated (R = 0.99) in our data base of 204 young and elderly subjects. Also, HOMA-S and its computer-model version are highly correlated (R = 0.99), whereas HOMA-B with insulin and C-peptide show R = 0.66.


    beta-CELL FUNCTION FROM IVGTT
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 
A variety of methods have been used to assess the beta-cell response to a glucose stimulus. The IVGTT is probably the most common (Table 1).

First-Phase Index Based on Insulin

The acute insulin response (AIR) is perhaps the most popular index of insulin secretion. After injection, glucose rapidly increases from ~90 to ~350 mg/dl. Plasma insulin concentration is measured in the first 10 min, and its area under the curve is calculated. What does AIR measure? It almost certainly reflects a nearly instantaneous release of insulin from previously docked granules that then distributes in plasma to produce the subsequent rapid rise and then fall in plasma insulin due to processing and docking of new granules. However, being based on insulin concentration, AIR also reflects hepatic insulin extraction, and since extraction differs depending on pattern and amount of insulin release, AIR does not provide an independent assessment of insulin secretion (41).

As discussed previously, an accurate beta-cell metric must account for insulin sensitivity. The IVGTT glucose minimal model Fig. 4, left, enables assessment of an index of insulin sensitivity, SIivgtt (4), which has been validated in numerous studies (see, for instance, Ref. 51). AIR is then multiplied by SIivgtt to calculate what commonly has been referred to as a disposition index, to determine whether insulin secretion is appropriate for the prevailing level of insulin action.


Figure 4
View larger version (13K):
[in this window]
[in a new window]

 
Fig. 4. The glucose minimal models allow estimation of insulin sensitivity (SI) from an intravenous glucose tolerance test (IVGTT; left) and an oral glucose tolerance test (OGTT) and meal (right).

 
First- and Second-Phase Indexes and Delay Based on C-Peptide

AIR has two major limitations. First, it is a composite "beta-cell function and hepatic insulin extraction" index, and second, it probes beta-cell behavior in a very brief time window and immediately after a markedly supraphysiological glucose stimulus.

beta-Cell function can be assessed from plasma glucose and C-peptide concentrations measured during a standard or insulin-modified IVGTT by using the minimal model shown in Fig. 5, left (59), which is based on the pioneering work of Grodsky and colleagues (31, 36). Use of C-peptide instead of insulin concentrations has the advantage that issues of hepatic insulin clearance are overcome. C-peptide kinetics is described by a two-compartment model whose parameters are usually determined, without loss of accuracy, with the population approach (62). Insulin secretion is made up of two components, first- and second-phase secretion. First-phase secretion portrays in the model a rapidly turning over compartment (2 min) and likely represents exocytosis of previously primed insulin secretory granules (commonly called readily releasable). It introduces a derivative control, since it is proportional to the rate of increase of glucose from basal up to the maximum through the parameter {Phi}1, which defines the first responsivity index (in contrast to AIR, {Phi}1 is a pure beta-cell function index; correlation between AIR and {Phi}1 in 204 individuals is 0.72). Second-phase insulin secretion is believed to be derived from the provision and/or docking of new insulin secretory granules that occurs in response to (i.e. proportional to) a given glucose concentration through the parameter {Phi}2, which defines the second-phase responsivity index, and reaches the releasable pool with a delay time constant, T. The meaning of {Phi}2 and T are readily envisioned by making reference to a thought experiment of an above-basal step increase of glucose: provision tends with time constant T toward a steady state that is linearly related to the glucose step size through parameter {Phi}2. T presumably represents the time required for new "readily releasable" granules to dock, be primed, and then be exocytosed. All these three ingredients, i.e. derivative term, delay, and presence of releasable pool, have been shown to be necessary for the model to accurately describe C-peptide data (59).


Figure 5
View larger version (10K):
[in this window]
[in a new window]

 
Fig. 5. The C-peptide minimal models allow estimation of beta-cell responsivity ({Phi}) from an IVGTT (left) and an OGTT and meal (right). C-peptide kinetics is described by a 2-compartment model: {Phi}1, first-phase responsivity index; {Phi}2, second-phase responsivity index; T, delay time constant; {Phi}d dynamic responsitivity index; {Phi}s stotic responsitivity index.

 
beta-Cell responsivity indexes can be usefully interpreted in terms of insulin secretion. To do this, insulin secretion during an IVGTT is decomposed (Fig. 6, left) into basal, first-phase, and second-phase components. Against this background it is easy to give an interpretation of the various indexes, summarized in Table 2. In addition to {Phi}1 and {Phi}2, basal responsivity, {Phi}b, also is of interest, since it gives a basal, nonstimulated index complementing the stimulated ones, {Phi}1 and {Phi}2. Finally, a single total index of stimulated beta-cell responsivity, {Phi}ivgtt, can be derived by properly combining {Phi}1 and {Phi}2. Disposition indexes can also be calculated by multiplying responsivity indices {Phi}1 and {Phi}2 by SIivgtt to determine whether that aspect of beta-cell function is appropriate for the level of insulin action (Table 2). Disposition indexes DI1 and DI2 measure beta-cell function in relation to insulin sensitivity under a glucose stimulus. This portrait can be usefully complemented by a basal disposition index, DIb, obtained by multiplying {Phi}b by HOMA-S (or QUICKI).


Figure 6
View larger version (21K):
[in this window]
[in a new window]

 
Fig. 6. Qualitative glucose stimulus and insulin secretion responses from an IVGTT (left) and an OGTT and meal (right). For both tests, insulin secretion and corresponding glucose stimulus components are identified, which allows an intuitive definition of the various beta-cell responsivity indexes (see Table 2).

 

View this table:
[in this window]
[in a new window]

 
Table 2. Minimal model indexes

 
Hepatic Insulin Extraction

Since plasma insulin concentrations are measured during the IVGTT for estimating insulin sensitivity, posthepatic insulin delivery rates can be calculated allowing estimation of hepatic insulin extraction during the test, HEivgtt, and in basal condition, HEb (57) (Table 2). To this end, the protocol of choice is an insulin-modified IVGTT, since the decay of insulin concentration observed after exogenous insulin administration facilitates a reliable estimation of insulin kinetics. However, a population approach, similar to that developed for C-peptide kinetics, is being developed for insulin kinetics, and preliminary results are very encouraging (13).

Figure 7, left, shows beta-cell responsivity, insulin sensitivity, hepatic extraction, and disposition index in 54 young and 159 elderly subjects, whereas Fig. 8 shows their basal counterparts (the glucose minimal model does not provide a basal insulin sensitivity index, and thus one can use HOMA-S or QUICKI to complete the basal picture). As is evident, the stimulated and basal index portraits provide important and complementary information that is discussed below. At this point we simply note that it is important to not just look at the relationship between beta-cell function and insulin sensitivity but also to consider hepatic insulin extraction (41).


Figure 7
View larger version (17K):
[in this window]
[in a new window]

 
Fig. 7. beta-Cell responsivity, insulin sensitivity, hepatic insulin extraction (HE), and disposition index (DI) in young vs. elderly subjects, obtained from IVGTT (left) and meal (right) following the IVGTT and meal models of Figs. 4 and 5. Results are shown as means ± SE. *P < 0.05. SIivgtt is expressed in dl·kg–1·min–1 per pM, instead of the most widely adopted unit in IVGTT literature studies (min–1 per pM), for comparison with SIoral. See text for detailed definitions.

 

Figure 8
View larger version (13K):
[in this window]
[in a new window]

 
Fig. 8. Basal beta-cell responsivity, insulin sensitivity, hepatic extraction, and disposition index in young vs. elderly subjects. See text for detailed definitions.

 

    beta-CELL FUNCTION FROM AN OGTT OR MIXED MEAL
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 
An oral glucose test differs from IVGTT in several important ways. These include the oral route of delivery, the associated incretin hormone secretion, the physiologically smoother pattern of changes in glucose, insulin, and C-peptide concentrations, and the presence of nonglucose nutrients stimulation, e.g., amino acids and fat, during a mixed meal.

beta-Cell Responsivities and Hepatic Insulin Extraction

beta-Cell function after an oral glucose challenge can be assessed using the oral minimal model, which interprets plasma C-peptide concentrations in relation to the observed changes in glucose concentration (8). All of the previous model ingredients employed in the IVGTT model were necessary with the exception of the fast-turning over insulin releasable pool (which is not evident under these conditions) to describe the data. In particular, both a rate of change of glucose component of insulin secretion and a delay between glucose stimulus and beta-cell response were necessary to fit the data (9). The oral model thus features a dynamic component that senses the rate of change of glucose concentration and a static component that represents the release of insulin that, after a delay, occurs in proportion to prevailing glucose concentration. The oral beta-cell model is shown in Fig. 5, right. The model has been successfully used by Steil et al. (52) for describing hyperglycemic clamp C-peptide data as well as meals, thus providing further independent evidence of its validity (see also comments in Ref. 14). Of interest, in contrast to the IVGTT model, where the derivative component of first-phase secretion was operative only during the first few minutes as the plasma glucose concentration increased from a "basal" to "maximal" concentration, the relatively gradual "bell-shaped" pattern in glucose concentrations observed during oral tests necessitated the presence of a secretion component proportional to the glucose rate of increase that contributed to the model for the first 60–90 min. In addition, and similar to the IVGTT, a component of insulin secretion proportional to glucose, characterized by a delay time T (presumably reflecting at least in part the time it takes for new granules to reach the releasable pool) that contributed throughout the experimental period was also necessary. The two components have been termed, respectively, dynamic and static, and the parameters responsible for them are termed dynamic ({Phi}d) and static ({Phi}s) responsivity indexes. As discussed above, this was markedly different from the IVGTT model, where the first-phase component only contributed during the first 4–6 min. Therefore, {Phi}d, and {Phi}s indexes (during an oral glucose challenge) are numerically different albeit related to first-phase {Phi}1 and second-phase {Phi}2 indexes (following intravenous glucose injection); the correlation in the 204 individuals was only 0.52 for both indexes. Thus it is probable that they are assessing different aspects of the insulin secretory pathway. In particular, {Phi}d presumably also reflects multiple distal steps including the rate of granule docking, priming, and exocytosis, whereas {Phi}s also reflects earlier steps, e.g., synthesis, process, and granule maturation.

Oral beta-cell responsivity indexes can be interpreted in terms of insulin secretion (Fig. 6, right), and they are summarized in Table 2. The basal responsivity index {Phi}b and total responsivity index {Phi}oral, which combines {Phi}d and {Phi}s, are also listed. The importance of {Phi}b is often underappreciated. For example, {Phi}b accounts for almost all of the differences when beta-cell function was compared in obese subjects before and after weight loss (12). HOMA-B correlates poorly in the 204 individuals with {Phi}b (R = 0.42, but HOMA-B with C-peptide improves to R = 0.66) and poorly with the stimulated indexes {Phi}d and {Phi}s (0.34 and 0.36, respectively); the same happens with IVGTT indexes {Phi}1 and {Phi}2 (0.39 and 0.40, respectively).

An accurate beta-cell metric must account for insulin sensitivity. Insulin sensitivity can also be accurately measured with the oral minimal model of Fig. 4, right (22). This model provides an index, SIoral (Table 2), which has been validated both against a multiple tracer meal protocol (21) and in an OGTT vs. euglycemic clamp study (24), showing a correlation of 0.86 and 0.81, respectively. SIoral and SIivgtt differ in that they are protocol dependent (26), but SIoral correlates well in the 204 individuals with SIivgtt (R = 0.74), whereas correlation with nonstimulated indexes HOMA-S and QUICKI is 0.50.

It is also of interest to assess the reproducibility of oral beta-cell function and insulin sensitivity indexes against that of IVGTT indexes reported previously (55). To do so, we have analyzed the meal data of Toffolo et al. (56). The results for {Phi}d, {Phi}s, and SIoral are shown in Table 3, where for the sake of comparison those of IVGTT (55) are also reported. The reproducibility of the indexes in the two tests is very similar, and one can safely assume a reproducibility between 20 and 30%.


View this table:
[in this window]
[in a new window]

 
Table 3. IVGTT and meal index reproducibility

 
The rich portrait of beta-cell function provided by the oral minimal model carries over to the disposition index beta-cell metric. Similarly to IVGTT, the oral model yields three disposition indexes, a dynamic (DId), a static (DIs), and an overall disposition index (DIoral) (Table 2), all probing different aspects of beta-cell function. In addition, as with IVGTT, a basal disposition index (DIb) can be calculated. As expected, there is virtually no relation with between DId and DIs, and DIb = {Phi}b x HOMA-S (or QUICKI) (in the 204 individuals, 0.12 for DId, 0.14 for DIs; similarly, for IVGTT: –0.07 for DI1, 0.03 for DI2).

Hepatic insulin extraction also can be estimated during an oral minimal test by following a strategy similar to that outlined for the IVGTT: an insulin model, where kinetics have been fixed by a population approach, can predict posthepatic delivery rate of insulin in plasma, which, combined with portal insulin delivery provided by the C-peptide model, allows the estimation of hepatic insulin extraction during the test, HEoral, and in basal conditions, HEb (Table 2).

Figure 7, right, documents the richness of information of the oral models by showing, respectively, indexes of beta-cell function, insulin sensitivity, hepatic insulin extraction, and disposition index obtained in 54 young and 159 elderly subjects from a mixed-meal study. Both IVGTT and oral models reveal the same defective trend of metabolic indexes in the elderly subjects. The basal indexes of Fig. 8 complement the stimulated indexes of Fig. 7, right. As expected from theory, the two portraits provide very different information. In the basal state, elderly subjects have beta-cell function, insulin sensitivity, and disposition index comparable, if not greater than, that of young subjects; only their hepatic extraction is higher. In contrast, the meal-stimulated state reveals the profound defects of all metabolic indexes in the elderly subjects. We comment further on this topic below.

Reduced Oral Protocol

An oral protocol that employs a reduced duration or number of samples while maintaining accuracy is potentially of considerable value, since it could facilitate the conduct of large-scale epidemiological and clinical trials. For the IVGTT minimal model (both standard and insulin modified), glucose and insulin concentrations must be measured for at least 3 h (and perhaps 4 h depending on glucose tolerance) to obtain a reliable measure of insulin action. In contrast, a reduced-sample oral minimal model enables insulin secretion and action to be reliably measured using a shorter protocol (2 h) and with only seven samples. This protocol was developed using a database of 100 OGTTs in which 11 samples were obtained over 5 h and 100 meal studies in which 21 samples were obtained over 7 h. These data established that a seven-sample protocol performed over 2 h after ingestion of either 75 g of glucose or a mixed meal enables accurate assessment of both beta-cell function and insulin sensitivity in nondiabetic humans (20). The resultant indexes obtained with the 2-h protocol were not significantly different and were very well correlated to those of the full protocol; Fig. 9 shows the OGTT results, but similar results have also been obtained for the meal. The proposed 2-h duration is the same as that of the standard OGTT and therefore does not extend the period of study. It also retains the typical 0- and 120-min samples with the addition of samples at 10, 20, 30, 60, and 90 min. Of note, samples at 10 and 20 min are essential for an accurate and precise estimation of dynamic beta-cell responsivity {Phi}d, which by definition relies on the data derived when glucose is increasing. The reduced protocol was developed from a database comprising individuals who had a wide range of glucose tolerance. A first study employing the seven-sample OGTT was recently published (46). However, people with marked fasting hyperglycemia were not studied. Additional studies are required to determine whether a similar approach can be used in individuals with more severe impairment of insulin secretion and insulin action, e.g., diabetes.


Figure 9
View larger version (20K):
[in this window]
[in a new window]

 
Fig. 9. Insulin sensitivity, beta-cell responsivity, and disposition index in OGTT full vs. reduced protocols. Results are shown as means ± SE.

 
Other Models

Other models have been proposed to assess beta-cell function during OGTT and meal test. The model proposed by Hovorka et al. (33) assumes an instantaneous linear control of glucose on insulin secretion; i.e., there is no delay between glucose stimulus and beta-cell response. The model proposed by Cretti et al. (18) describes insulin secretion with the static component of glucose control of the C-peptide minimal model; thus it is characterized by a delay but does not include any dynamic, i.e., rate of change, glucose control. Interestingly, the same authors have recently included a dynamic control to describe first-phase secretion in a subsequent report (64). The model proposed in by Mari et al. (38), like the oral model shown in Fig. 3, right, has both a proportional component and a component responsive to the rate of change of glucose, but there is no delay between glucose signaling and supply of new insulin to the circulation. The authors choose to account for the expected inability of a proportional plus derivative glucose control to account for C-peptide measurements with a time-varying term correcting only the static component of insulin secretion, which has been called the potentiation factor. In simple words, the potentiation factor is a time-varying correction term that mathematically compensates for the proportional plus derivative description deficiency. Given this framework, the physiological interpretation of this factor is difficult. The authors have hypothesized that this correction term is linked in some fashion to incretin- and/or glucose-mediated factors (37, 38). However, we have recently shown in an OGTT and matched intravenous study (14) that this potentiation factor (38) is not related to the incretin effect in that there was no difference between the potentiation factor during OGTT and matched intravenous study (Fig. 10). It remains possible that this time-varying factor, by sustaining insulin secretion after the glucose stimulus, is simply accounting for the physiological delay occurring between glucose signaling and provision of new insulin to the readily releasable pool. The model also deserves some comments in terms of modeling methodology. At variance with all the other models (8, 18, 33) that are numerically identified by standard nonlinear least squares and maximum likelihood methods (15), this model requires a less transparent strategy that also bears some degree of subjectivity. In fact, the reconstruction of the time course of this potentiation factor starting from the sole C-peptide measurements requires a smoothness deconvolution procedure governed by two unknown parameters to obtain the final solution. The criterion chosen for their estimation is the discrepancy criterion, which is known to provide oversmoothing (15). In addition, it is not uncommon when running this model to find multiple solutions in the same individual and, thus, different potentiation factor time courses.


Figure 10
View larger version (9K):
[in this window]
[in a new window]

 
Fig. 10. The time course of the potentiation factor of the model (30) during an OGTT (solid line) and during an isoglycemic intravenous glucose infusion (dashed line).

 

    DISPOSITION INDEX
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 
It is important to revisit in the context of IVGTT, where it was first introduced (4), the classic measure of beta-cell function in relation to insulin action provided by the disposition index. The disposition index was introduced as a conceptual surrogate of the efficiency of glucose homeostasis in a given individual, which is the ability of beta-cells to upregulate insulin secretion in response to a decrease of insulin sensitivity, and is thus a measure of beta-cell functionality. Numerous studies have confirmed the ability of beta-cells to compensate for insulin resistance, and the disposition index relationship has recently received the status of the hyperbolic law of glucose tolerance (54). However, its conceptual simplicity hides some methodological issues which must be addressed in more depth (see also Ref. 29). More specifically, the questions we address are as follows: Is it true that the hyperbolic relationship DI1 = {Phi}1 x SIivgtt = constant and DI2 = {Phi}2 x SIivgtt = constant holds in a population? How should DI1 and DI2 be used in comparing populations, i.e., should the individual values be averaged, or should the disposition index be estimated directly in the population? Should the disposition index be calculated from a single or different tests? Is insulin action the single normalization factor for beta-cell function, or should hepatic insulin extraction, for example, come into play as an additional ingredient?

Methodology

We start by noting that there are some methodological issues behind these questions that have been dealt with differently in different studies, e.g., in Refs. 35 and 61 vs. Refs. 30 and 45. First, in testing whether the disposition index relationships are constant, it is not correct to use ordinary regression where one of the variables is assumed with no errors. This is done, for example, in Ref. 30, where SIivgtt is assumed as the independent and AIR as the dependent variable, and in Ref. 45, where the opposite is assumed. All indexes {Phi}1 or AIR, {Phi}2, and SIivgtt have errors, and thus regression with error in two variables must be used, e.g., Refs. 10 and 17. Second, regression should be performed on the original variables, not on the log-transformed ones; in fact, with log transformation, errors are no longer additive, i.e., log ({Phi}1 + error) is not log {Phi}1 + log error, and it is not correct to apply linear regression methods, which assume additive errors. This is done in Refs. 35 and 61, where linear regression on log-transformed data with error in both AIR and SIivgtt is considered.

Figures 11 and 12 portray our IVGTT beta-cell responsivities {Phi}1 and {Phi}2 and insulin sensitivity SIivgtt in 59 young and 145 elderly subjects, respectively. We have fitted these data with the nonlinear inverse relationships DI1 = {Phi}1 x SIFormula and DI2 = {Phi}2 x SIFormula: if {alpha}1,{alpha}2 = 1, one has the classic disposition index hyperbola, i.e., DI = beta-cell function x insulin sensitivity = constant; if {alpha}1,{alpha}2!=1, this is no longer true, and glucose tolerance is characterized by two (DI and {alpha}) instead of one (DI) parameter. Parameters DI and {alpha} were estimated by nonlinear regression in the original variables. Instead of using the cost function proposed in Ref. 49, which was developed for linear regression, we implemented the following. For each data point, the minimum weighted distance to the equation y = DI/(x{alpha}) was calculated. The x component of this distance was weighted according to error in the x variable (e.g., SIivgtt), and the y component according to that in the y variable (e.g., {Phi}1), obtained from the numerical identification of glucose and C-peptide models, respectively. The sum of squares of these weighted distances was minimized, and estimates of {alpha} and DI were obtained. Confidence intervals were also calculated to take into account the uncertainty of the estimates of both {alpha} and DI. Our results show that the values of {alpha} obtained for first-phase DI in elderly subjects and second-phase DI in young and elderly subjects are significantly different from 1, whereas the value of first-phase DI in young subjects is not.


Figure 11
View larger version (32K):
[in this window]
[in a new window]

 
Fig. 11. First-phase (top) and second-phase (bottom) disposition index plots with 95% confidence intervals in young subjects when individual DI values are averaged (dashed lines) and when the equation DI = beta-cell function x (insulin sensitivity){alpha} is fitted (solid lines). For each data point, bars indicate precision of {Phi}1, {Phi}2, and SIivgtt estimates.

 

Figure 12
View larger version (39K):
[in this window]
[in a new window]

 
Fig. 12. First-phase (top) and second-phase (bottom) disposition index plots with 95% confidence intervals in elderly subjects when individual DI are averaged (dashed lines) and when the equation DI = beta-cell function x (insulin sensitivity){alpha} is fitted (solid lines). For each data point, bars indicate precision of {Phi}1, {Phi}2. and SIivgtt estimates.

 
The methodology for estimating DI1, {alpha}1 and DI2, {alpha}2 is of crucial importance. For instance, in elderly subjects we have {alpha}1 = 0.68 (0.48–0.88) with DI1 = 332 (208–455) (Fig. 11, top). If we had used regression with error in two variables but on log-transformed data, {alpha}1 would have been 0.76 (0.56–0.96) with DI1 = 559 (328–790). If we had performed a regression on original data by considering SIivgtt as an independent variable, {alpha}1 would have been 0.19 (0.05–0.33) with DI1 = 135 (107–164).

Finally, the importance of also obtaining reliable confidence intervals in the population is worth emphasizing by looking back to Fig. 2. The normality range in the young and elderly subjects with impaired fasting glucose/tolerance can be compared for a targeted treatment.

Individual vs. Population Estimation

Two comments are in order: first, populations can be described by an {alpha} value that is not equal to 1; second, as expected from theory, the value of the disposition index obtained by averaging individuals is different from that obtained by estimating disposition index parameters DI1, {alpha}1 and DI2, {alpha}2 in the population, even when {alpha}1 and {alpha}2 are close to 1. Therefore, the correct approach for comparing different populations is to estimate the two disposition index parameters ({alpha} and DI) in each population. This was possible because of the availability of two large and homogeneous populations, i.e., young and elderly subjects are two normoglycemic homogenous populations (4.8 ± 0.1 vs. 5.2 ± 0.1 mM) with age being the only discriminatory variable (23 ± 0.4 vs. 69 ± 0.5 yr). In our young vs. elderly subjects, the statistical differences between disposition indexes observed by the population and individual averaging strategy are the same (Figs. 11 and 12), but this may be due to the homogeneity and numerousness of the studied population.

Is the population estimation strategy also the way to go when the numerousness of the population is small, or is the individual averaging the only possibility? To address this question, we created two situations in which only n = 15 or n = 30 young vs. elderly subjects were compared, randomly extracted from our database of young and elderly subjects. We tested the n = 15 and n = 30 young vs. elderly subjects against the 54 young vs. 159 elderly subject "truth" by considering significantly different first- and second-phase disposition indexes if at least one of the two parameters DI1, {alpha}1 or DI2, {alpha}2 were significantly different. Our results show that the population performs better than the individual averaging strategy in recovering the true significant difference: for first-phase disposition index, 97 vs. 95% and 99 vs. 100% tests (out of 1,000 random sets) agree with truth for n = 15 and n = 30, respectively, whereas for second-phase disposition index, 37 vs. 33% and 77 vs. 66% for n = 15 and n = 30, respectively. These results also indicate that the numerousness of the population is critical, particularly for second-phase disposition index, since with n = 30 the population strategy performed two times better than with n = 15, but there was still 25% probability of error (probably due to the smaller difference in second-phase with respect to first-phase disposition index).

Same vs. Different Test

Another relevant issue concerns the importance of measuring insulin secretion and action with the same test when comparing populations. This is often not the case. For instance, insulin secretion is often assessed by IVGTT AIR or oral test insulinogenic index (53), and insulin action via clamp or oral composite insulin sensitivity index (39). However, albeit some of these beta-cell function and insulin sensitivity indexes, e.g., AIR and clamp insulin sensitivity, are well correlated with IVGTT {Phi}1 and SIivgtt, their actual values differ and are protocol dependent (see Ref. 26 for insulin action). This means that the disposition index will be different with different metrics and thus impossible to compare. This problem is avoided when the same test (e.g., IVGTT or oral test) is used to simultaneously measure both beta-cell function and insulin sensitivity with two different models, the C-peptide and glucose minimal models, from C-peptide and glucose data and with insulin and glucose data, respectively.

Hepatic Extraction Dimension

The results of Fig. 7 support consideration of hepatic insulin extraction in addition to the beta-cell function and insulin sensitivity glucose tolerance picture. We have examined the interrelationship of beta-cell responsivity and insulin sensitivity with hepatic insulin extraction, where this last is expressed as 1 – HEivgtt, i.e., the fraction that reaches peripheral tissues. We observed a nonpatterned relation of hepatic insulin extraction with both beta-cell function and insulin sensitivity in both young and elderly subjects (data not shown). Of note, however, this relationship differs with age, i.e., in elderly subjects a smaller proportion of secreted insulin reaches peripheral tissues (see below).

Basal Complement

All the above portrays beta-cell function in relation to insulin sensitivity under glucose-stimulated conditions. However, it is important to complement this picture with the basal one by examining the basal disposition index: DIb = {Phi}b x HOMA-S (or QUICKI). Figure 13 shows DIb for young (top) and elderly subjects (bottom), obtained with the population estimation assuming both {Phi}b and HOMA-S have errors (reflecting plasma concentration measurement error). In the basal state, elderly individuals show, in agreement with Fig. 8, a better ability of beta-cell function to compensate for insulin resistance compared with young subjects. As under the IVGTT stimulated condition, we observed a nonpatterned relation between 1 – HEb and HOMA-S (or QUICKI) while confirming results of Fig. 8, i.e., in elderly subjects a smaller proportion of insulin secretion reaches peripheral tissues in the basal state as well.


Figure 13
View larger version (35K):
[in this window]
[in a new window]

 
Fig. 13. Basal disposition index in young (top) and elderly (bottom) subjects. For each data point, bars indicate precision of {Phi}b and HOMA-S estimates.

 

    SUMMARY
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 
Insulin secretion as well as insulin action and hepatic insulin extraction are important determinants of carbohydrate, fat, and protein metabolism. Ideally, these should be assessed using a single, simple physiological test in the presence of glucose, amino acids, incretins, and neural signals. As discussed in this Perspective, the oral minimal model using an OGTT or a mixed meal can be used to simultaneously and quantitatively measure beta-cell function, insulin sensitivity, and hepatic insulin extraction. The widely used IVGTT minimal model, although nonphysiological, provides useful insight into the regulation of insulin secretion and action. We have attempted to highlight the unique aspects of both approaches, particularly in relation to their ability to assess important but differing cellular events in the beta-cell secretory cascade. The oral method, by quantitatively portraying the complex relationships among beta-cell function, insulin sensitivity, and hepatic insulin extraction, has the potential to provide novel insights regarding the regulation of fasting and postprandial glucose metabolism in nondiabetic and diabetic humans and has been recently employed in several studies (3, 6, 7, 42, 46).


    GRANTS
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 
This study was supported by National Institutes of Health Grants EB-01975, AG-14383, DK-29953, and RR-00585 and by Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Italy.


    ACKNOWLEDGMENTS
 
We thank Dr. Rita Basu and Ananda Basu for helpful discussions on modeling results of the 204 subjects who underwent both IVGTT and meal tolerance tests. We offer additional thanks to Dr. Gianluigi Pillonetto for thoughtful comments on literature models.


    FOOTNOTES
 

Address for reprint requests and other correspondence: C. Cobelli, Dept. of Information Engineering, Univ. of Padua, Via Gradenigo 6/B, 35131 Padua, Italy (e-mail: cobelli{at}dei.unipd.it)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 WHY IT IS DIFFICULT
 CELLULAR EVENTS IN beta-CELLS
 beta-CELL FUNCTION FROM BASAL...
 beta-CELL FUNCTION FROM IVGTT
 beta-CELL FUNCTION FROM AN...
 DISPOSITION INDEX
 SUMMARY
 GRANTS
 REFERENCES
 

  1. Barg S, Eliasson L, Renstrom E, Rorsman P. A subset of 50 secretory granules in close contact with L-type Ca2+ channels accounts for first-phase insulin secretion in mouse beta-cells. Diabetes 51: S74–S82, 2002.[Abstract/Free Full Text]
  2. Basu R, Dalla Man C, Campioni M, Basu A, Klee G, Toffolo G, Cobelli C, Rizza RA. Effects of age and gender on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes 55: 2001–2014, 2006.[Abstract/Free Full Text]
  3. Basu R, Dalla Man C, Campioni M, Basu A, Nair SK, Jensen MD, Koshla S, Klee G, Toffolo G, Cobelli C, Rizza RA. Two years of treatment with dehydroepianolrosterone does not improve insulin secretion, action, or post prandial glucose further in elderly men or women. Diabetes 56: 753–766, 2007.[Abstract/Free Full Text]
  4. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell sensitivity from the response to intravenous glucose. J Clin Invest 68: 1456–1467, 1981.[Web of Science][Medline]
  5. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol Endocrinol Metab Gastrointest Physiol 236: E667–E677, 1979.[Abstract/Free Full Text]
  6. Bock G, Dalla Man C, Campioni C, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 55: 3536–3549, 2006.[Abstract/Free Full Text]
  7. Bock G, Dalla Man C, Campioni C, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R. Effects of nonglucose nutrients on insulin secretion and action in people with pre-diabetes. Diabetes 56: 1113–1119, 2007.[Abstract/Free Full Text]
  8. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 50: 150 –158, 2001.[Abstract/Free Full Text]
  9. Breda E, Toffolo G, Polonsky KS, Cobelli C. Insulin release in impaired glucose tolerance: oral minimal model predicts normal sensitivity to glucose but defective response times. Diabetes 51: S227–S233, 2002.[Abstract/Free Full Text]
  10. Brown ML. Robust line estimation with errors in both variables. J Am Stat Assoc 77: 71–79, 1982.[CrossRef][Web of Science]
  11. Byrne MM, Sturis J, Polonsky KS. Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol Endocrinol Metab 268: E21–E27, 1995.[Abstract/Free Full Text]
  12. Camastra S, Manco M, Mari A, Baldi S, Gastaldelli A, Greco AV, Mingrone G, Ferrannini E. beta-Cell function in morbidly obese subjects during free living: long-term effects of weight loss. Diabetes 54: 2382–2389, 2005.[Abstract/Free Full Text]
  13. Campioni M, Toffolo G, Rizza R, Cobelli C. Estimation of hepatic insulin extraction during im-ivgtt: individual vs. standard kinetic parameters. In: International Federation for Medical and Biological Engineering Proceedings MEDICON and Health Telematics 2004. X Mediterranean Conference on Medical and Biological Engineering. Ischia, Italy: 2004, vol. 6.
  14. Campioni M, Toffolo G, Shuster LT, Service J, Rizza R, Cobelli C. Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab 292: E54–E60, 2007.[Abstract/Free Full Text]
  15. Carson ER, Cobelli C. Modelling Methodology for Physiology and Medicine. San Diego, CA: Academic, 2001.
  16. Caumo A, Perseghin G, Brunani A, Luzi L. New insights on the simultaneous assessment of insulin sensitivity and beta-cell function with the HOMA2 method. Diabetes Care 29: 2733–2734, 2006.[Free Full Text]
  17. Cheng CL, Van Ness J. Robust calibration. Technometrics 39: 401–411, 1997.[CrossRef][Web of Science]
  18. Cretti A, Lehtovirta M, Bonora E, Brunato B, Zenti MG, Tosi F, Caputo M, Caruso B, Groop LC, Muggeo M, Bonadonna RC. Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion. Eur J Clin Invest 31: 405–416, 2001.[CrossRef][Web of Science][Medline]
  19. Curry DL, Bennett LL, Grodsky GM. Dynamics of insulin secretion by the perfused rat pancreas. Endocrinology 83: 572–584, 1968.[Abstract/Free Full Text]
  20. Dalla Man C, Campioni M, Polonsky KS, Basu R, Rizza RA, Toffolo G, Cobelli C. Two-hour seven-sample oral glucose tolerance test, and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes 54: 3265–3273, 2005.[Abstract/Free Full Text]
  21. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C. Minimal model estimation of glucose absorption and insulin sensitivity from an oral test: validation with a tracer method. Am J Physiol Endocrinol Metab 287: E637–E643, 2004.[Abstract/Free Full Text]
  22. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C. Measurement of selective effect of insulin on glucose disposal from labeled glucose oral test minimal model. Am J Physiol Endocrinol Metab 289: E909–E914, 2005.[Abstract/Free Full Text]
  23. Dalla Man C, Caumo A, Cobelli C. The oral glucose minimal model: estimation of insulin sensitivity from a meal test. IEEE Trans Biomed Eng 49: 419–429, 2002.[CrossRef][Web of Science][Medline]
  24. Dalla Man C, Yarasheski KE, Caumo A, Robertson H, Toffolo G, Polonsky KS, Cobelli C. Insulin sensitivity by oral glucose minimal models: validation against clamp. Am J Physiol Endocrinol Metab 289: E954–E959, 2005.[Abstract/Free Full Text]
  25. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 237: E214–E223, 1979.[Abstract/Free Full Text]
  26. Doeden B, Rizza R. Use of a variable insulin infusion to assess insulin action in obesity: defects in both the kinetics and amplitude of response. J Clin Endocrinol Metab 64: 902–908, 1987.[Abstract/Free Full Text]
  27. Duncan RR, Greaves J, Wiegand UK, Matskevich I, Bodammer G, Apps DK, Shipston MJ, Chow RH. Functional, and spatial segregation of secretory vesicle pools according to vesicle age. Nature 422: 176–180, 2003.[CrossRef][Medline]
  28. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 51: 520–528, 1980.[Abstract/Free Full Text]
  29. Ferrannini E, Mari A. beta-Cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 47: 943–956, 2004.[CrossRef][Web of Science][Medline]
  30. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals. The Insulin Resistance Atherosclerosis Study. Diabetes 55: 1114–1120, 2006.[Abstract/Free Full Text]
  31. Grodsky GM. A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. J Clin Invest 51: 2047–2059, 1972.[Web of Science][Medline]
  32. Grodsky GM, Curry D, Landahl H, Bennett L. Further studies on the dynamic aspects of insulin release in vitro with evidence for a two-compartmental storage system [Multiple languages]. Acta Diabetol Lat 6, Suppl 1: 554–578, 1969.[Medline]
  33. Hovorka R, Chassin L, Luzio SD, Playle R, Owens DR. Pancreatic beta-cell responsiveness during meal tolerance test: model assessment in normal subjects and subjects with newly diagnosed non-insulin-dependent diabetes mellitus. Clin Endocrinol Metab 83: 744–750, 1998.[CrossRef]
  34. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402–2410, 2000.[Abstract/Free Full Text]
  35. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JP, Palner JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663–1672, 1993.[Abstract]
  36. Licko V, Silvers A. Open-loop glucose-insulin control with threshold secretory mechanism: analysis of intravenous glucose tolerance tests in man. Math Biosci 27: 319–332, 1975.[CrossRef]
  37. Mari A, Gastaldelli A, Natali A, Ostergard T, Schmitz O, Ferrannini E. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests. Am J Physiol Endocrinol Metab 288: E541–E546, 2005.[Abstract/Free Full Text]
  38. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283: E1159–E1166, 2002.[Abstract/Free Full Text]
  39. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462–1470, 1999.[Abstract/Free Full Text]
  40. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419, 1985.[CrossRef][Web of Science][Medline]
  41. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 54: 1649–1656, 2005.[Abstract/Free Full Text]
  42. Nair KS, Rizza RA, O'Brein P, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ, Smith GE, Khosla S, Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355: 1647–1659, 2006.[Abstract/Free Full Text]
  43. Ohara-Imaizumi M, Nishiwaki C, Kikuta T, Nagai S, Nakamichi Y, Nagamatsu S. TIRF imaging of docking and fusion of single insulin granule motion in primary rat pancreatic beta-cells: different behaviour of granule motion between normal and Goto-Kakizaki diabetic rat beta-cells. Biochem J 381: 13–18, 2004.[CrossRef][Web of Science][Medline]
  44. Olofsson CS, Gopel SO, Barg S, Galvanovskis J, Ma X, Salehi A, Rorsman P, Eliasson L. Fast insulin secretion reflects exocytosis of docked granules in mouse pancreatic B-cells. Pflügers Arch 444: 43–51, 2002.[CrossRef][Web of Science][Medline]
  45. Pacini G, Thomaseth K, Ahrén B. Contribution to glucose intolerance of insulin-independent vs. insulin-dependent mechanisms in mice. Am J Physiol Endocrinol Metab 281: E693–E703, 2001.[Abstract/Free Full Text]
  46. Petersen FK, Dufour S, Feng J, Befroy D, Dzuira J, Dalla Man C, Cobelli C, Shulman G. Increased prevalence of insulin resistance and non-alcoholic fatty liver disease in Asian Indian men. Proc Natl Acad Sci USA 103: 18273–18277, 2006.[Abstract/Free Full Text]
  47. Polonsky KS, Given BD, Pugh W, Licinio-Paixao J, Thompson JE, Karrison T, Rubenstein AH. Calculation of the systemic delivery rate of insulin in normal man. J Clin Endocrinol Metab 63: 113–118, 1986.[Abstract/Free Full Text]
  48. Pouli AE, Karagenc N, Wasmeier C, Hutton JC, Bright N, Arden S, Schofield JG, Rutter GA. A phogrin-aequorin chimaera to image free Ca2+ in the vicinity of secretory granules. Biochem J 330: 1399–1404, 1998.[Web of Science][Medline]
  49. Riggs DS, Guarnieri JA, Addelman S. Fitting straight lines when both variables are subject to error. Life Sci 22: 1305–1360, 1978.[CrossRef][Web of Science][Medline]
  50. Rutter GA. Visualising insulin secretion. The Minkowski Lecture 2004. Diabetologia 47: 1861–1872, 2004.[CrossRef][Web of Science][Medline]
  51. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen YD, Sands RE, Pei D, Savage PJ, Bergman RN. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes 43: 1114–1121, 1994.[Abstract]
  52. Steil GM, Hwu C, Janowski R, Hariri F, Jinagouda S, Darwin C, Tadros S, Rebrin K, Saad MF. Evaluation of insulin sensitivity and beta-cell function indexes obtained from minimal model analysis of a meal tolerance test. Diabetes 53: 1201–1207, 2004.[Abstract/Free Full Text]
  53. Stumvoll M, Fritsche A, Stefan N, Haring H. A 60 minute hyperglycemic clamp is sufficient to assess both phases of insulin secretion. Horm Metab Res 32: 230–232, 2000.[Web of Science][Medline]
  54. Stumvoll M, Tataranni PA, Bogardus C. The hyperbolic law: a 25-year perspective. Diabetologia 48: 207–209, 2005.[CrossRef][Web of Science][Medline]
  55. Sunehag AL, Treuth MS, Toffolo G, Butte NF, Cobelli C, Bier DM, Haymond MW. Glucose production, gluconeogenesis, and insulin sensitivity in children and adolescents: an evaluation of their reproducibility. Pediatr Res 50: 115–123, 2001.[Web of Science][Medline]
  56. Toffolo G, Basu R, Dalla Man C, Rizza R, Cobelli C. Assessment of postprandial glucose metabolism: conventional dual- vs. triple-tracer method. Am J Physiol Endocrinol Metab 291: E800–E806, 2006.[Abstract/Free Full Text]
  57. Toffolo G, Campioni M, Basu R, Rizza RA, Cobelli C. A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab 290: E169–E176, 2006.[Abstract/Free Full Text]
  58. Toffolo G, Cobelli C. The hot IVGTT two-compartment minimal model: an improved version. Am J Physiol Endocrinol Metab 284: E317–E321, 2003.[Abstract/Free Full Text]
  59. Toffolo G, De Grandi F, Cobelli C. Estimation of beta-cell sensitivity from intravenous glucose tolerance test C-peptide data. Knowledge of the kinetics avoids errors in modeling the secretion. Diabetes 44: 845–854, 1995.[Abstract]
  60. Tsuboi T, Rutter GA. Multiple forms of "kiss-and-run" exocytosis revealed by evanescent wave microscopy. Curr Biol 13: 563–567, 2003.[CrossRef][Web of Science][Medline]
  61. Utzschneider KM, Carr DB, Hull L, Kodama K, Shofer JB, Retzlaff BM, Knopp RH, Kahn SE. Impact of intra-abdominal fat and age on insulin sensitivity and beta-cell function. Diabetes 53: 2867–2872, 2004.[Abstract/Free Full Text]
  62. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41: 368–377, 1992.[Abstract]
  63. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27: 1487–1495, 2004.[Abstract/Free Full Text]
  64. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R. beta-Cell function across the spectrum of glucose tolerance in obese youth. Diabetes 54: 1735–1743, 2005.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
R. A. Howlett, S. D. Kirkton, N. C. Gonzalez, H. E. Wagner, S. L. Britton, L. G. Koch, and P. D. Wagner
Peripheral oxygen transport and utilization in rats following continued selective breeding for endurance running capacity
J Appl Physiol, June 1, 2009; 106(6): 1819 - 1825.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
S. D. Kirkton, R. A. Howlett, N. C. Gonzalez, P. G. Giuliano, S. L. Britton, L. G. Koch, H. E. Wagner, and P. D. Wagner
Continued artificial selection for running endurance in rats is associated with improved lung function
J Appl Physiol, June 1, 2009; 106(6): 1810 - 1818.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
P. Poulsen, L. G. Grunnet, K. Pilgaard, H. Storgaard, A. Alibegovic, M. P. Sonne, B. Carstensen, H. Beck-Nielsen, and A. Vaag
Increased Risk of Type 2 Diabetes in Elderly Twins
Diabetes, June 1, 2009; 58(6): 1350 - 1355.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
C. Brøns, C. B. Jensen, H. Storgaard, N. J. Hiscock, A. White, J. S. Appel, S. Jacobsen, E. Nilsson, C. M. Larsen, A. Astrup, et al.
Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men
J. Physiol., May 1, 2009; 587(10): 2387 - 2397.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
A. M.G. Cali, C. D. Man, C. Cobelli, J. Dziura, A. Seyal, M. Shaw, K. Allen, S. Chen, and S. Caprio
Primary Defects in {beta}-Cell Function Further Exacerbated by Worsening of Insulin Resistance Mark the Development of Impaired Glucose Tolerance in Obese Adolescents
Diabetes Care, March 1, 2009; 32(3): 456 - 461.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
X. Zhao, A. Peter, J. Fritsche, M. Elcnerova, A. Fritsche, H.-U. Haring, E. D. Schleicher, G. Xu, and R. Lehmann
Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at?
Am J Physiol Endocrinol Metab, February 1, 2009; 296(2): E384 - E393.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
P. B Higgins, J. R Fernandez, W T. Garvey, W. M Granger, and B. A Gower
Entero-insular axis and postprandial insulin differences in African American and European American children
Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1277 - 1283.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc AHome page
M. G. Pedersen, A. Corradin, G. M Toffolo, and C. Cobelli
A subcellular model of glucose-stimulated pancreatic insulin secretion
Phil Trans R Soc A, October 13, 2008; 366(1880): 3525 - 3543.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. Muniyappa, S. Lee, H. Chen, and M. J. Quon
Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage
Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E15 - E26.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/1/E1    most recent
00421.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cobelli, C.
Right arrow Articles by Rizza, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cobelli, C.
Right arrow Articles by Rizza, R.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.